A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)

Study Summary

The purpose of this study is to establish the tolerability, preliminary efficacy, and pharmacokinetics of CC-97540 in participants with severe, refractory autoimmune diseases (Breakfree-1).

Conditions

Systemic Lupus Erythematosus Idiopathic Inflammatory Myopathy Systemic Sclerosis Rheumatoid Arthritis

Interventions / Drugs

CC-97540 Fludarabine Cyclophosphamide Tocilizumab

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment270 participants

Primary Completion—

Lead SponsorJuno Therapeutics, Inc., a Bristol-Myers Squibb Company

Data Retrieved2026-04-11 04:08:14.746430+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.